Review Article
Genetic Markers of Cardiovascular Disease in Rheumatoid Arthritis

Luis Rodríguez-Rodríguez,1,2 Raquel López-Meijas,3 Mercedes García-Bermúdez,2 Carlos González-Juanatey,4 Miguel A. González-Gay,3 and Javier Martín2

1 Department of Rheumatology, Hospital Clínico San Carlos, c/Profesor Martín Lagos s/n, 28040 Madrid, Spain
2 Instituto de Parasitología y Biomedicina López-Neyra, CSIC, Parque Tecnológico de Ciencias de la Salud, Avenida del Conocimiento s/n, Armilla, 18100 Granada, Spain
3 Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, IFIMA, Avenida Herrera Oria s/n, 39011 Santander, Spain
4 Cardiology Division, Hospital Xeral-Calde, c/Dr. Ochoa s/n, 27004 Lugo, Spain

Correspondence should be addressed to Javier Martín, martin@ipb.csic.es

Received 9 April 2012; Accepted 28 May 2012

Academic Editor: Patrick Dessein

Cardiovascular (CV) disease is the most common cause of premature mortality in patients with rheumatoid arthritis (RA). It is the result of an accelerated atherosclerotic process. Both RA and atherosclerosis are complex polygenic diseases. Besides traditional CV risk factors and chronic inflammation, a number of studies have confirmed the role of genetic factors in the development of the atherogenesis observed in RA. In this regard, besides a strong association between the HLA-DRB1∗04 shared epitope alleles and both endothelial dysfunction, an early step in the atherosclerotic process, and clinically evident CV disease, other polymorphisms belonging to genes implicated in inflammatory and metabolic pathways, located inside and outside the HLA region, such as the 308 variant (G > A, rs1800629) of the TNFA locus, the rs1801131 polymorphism (A > C; position +1298) of the MTHFR locus, or a deletion of 32 base pairs on the CCR5 gene, seem to be associated with the risk of CV disease in patients with RA. Despite considerable effort to decipher the genetic basis of CV disease in RA, further studies are required to better establish the genetic influence in the increased risk of CV events observed in patients with RA.

1. Introduction

Many epidemiological studies have reported in a consistent way an increased risk of nearly all forms of cardiovascular (CV) disease, a higher prevalence of subclinical atherosclerosis, and an increased CV mortality among rheumatoid arthritis (RA) patients [1, 2]. However, traditional CV risk factors, such as hypertension or diabetes mellitus, are not substantially different in RA compared to general population [3, 4]. Therefore, these risk factors may not account for the difference in risk between RA and the general population, and RA-associated factors, such as systemic inflammation, must be the main contributors to the observed gap [5].

Both RA and atherosclerosis are chronic inflammatory diseases [6, 7] that exhibit similar pathophysiological mechanisms [8], and that display a strong genetic component of susceptibility [9–11]. RA has an estimated heritability of up to 60% [12] and CV disease in the general population of up to 30–60% [13]. Besides, a specific genetic background may contribute to the development of both diseases [14].

Subclinical atherosclerosis is present in patients with RA [15, 16]. Noninvasive surrogate markers of atherosclerosis, such as the presence of endothelial dysfunction (established as an impaired flow-mediated endothelium-dependent vasodilatation FMD by brachial ultrasonography) or an abnormally increased carotid intima-media (cIMT) wall thickness and the presence of carotid plaques in the carotid artery (disclosed by carotid ultrasonography) are useful tools to establish a subgroup of RA patients with high risk of CV events [15–18].
Multiple variants in multiple genes have been investigated regarding their association with clinical and subclinical CV disease, traditional CV risk factors, and CV mortality.

2. HLA and Related Genes

Alleles from the HLA-DRB1 gene are not only risk factors for RA but also for CV disease (especially the HLA-DRB1*0404 allele) [19] (Table 1). Carriers of two copies of the shared epitope (SE) alleles also were associated with about a two-fold increase of mortality from CV disease [19, 20], particularly from ischemic heart disease (IHD) [21]. When specific SE genotypes were analyzed, the HLA-DRB1*0104 combination conferred the highest risk of mortality from CV disease, regardless of the duration of the disease [19–21].

Also, this combination resulted as predictive of mortality due to IHD independently of the inflammatory burden [21]. Furthermore, HLA-DRB1*04 SE alleles, in particular HLA-DRB1*0404, were associated with endothelial dysfunction, manifested by an impaired FMD [22, 49] and presence of atherosclerotic plaques [23]. An interaction between alleles of the HLA-DRB1 gene and other CV risk factors, such as the presence of anti-CCP (which seems to be associated with the presence of preclinical atherosclerosis [50]) has been observed. The combination of carrying two copies of the SE alleles, in the presence of anti-CCP and with a smoking background, appears to confer a very high risk of premature death from CV disease [20].

MHC class II genes expression is regulated by the class II transactivator [51], a protein that acts as a scaffold for the assembly of various transcription factors. This protein is expressed by cells from the atherosclerotic plaque, playing an important role in its development and complication [52]. Two variants of this gene were analyzed by our group, regarding their association with CV disease in two pooled cohorts of Spanish RA patients of Caucasian ancestry [25]. A polymorphism located in the 5′ flanking region at −168 (A > G; rs3087456), previously associated to a lower expression of MHC2TA and to a higher risk both of RA and IHD [53], and the variant rs4774, located at position +1632 (G > C; amino acid substitution, glycine to alanine, at codon position 500). Neither of them, either isolated or in combination, showed a significant association with a higher risk of clinical or subclinical CV disease [24].

3. TNF Superfamily Genes

TNF-α is a cytokine with pleiotropic and redundant actions. TNF-α is also a major regulator of the synthesis of acute-phase reactants by the liver [62]. This cytokine is produced by a wide variety of cells, and it is involved in both RA and atherosclerosis pathogenesis [63, 64]: circulating IL-6 concentration has been associated with endothelial activation and treatment with traditional disease modifying antirheumatic drugs, resulting in a suppression of IL-6, has been associated to a reduced endothelial activation in patients with RA [65, 66]. Three polymorphisms of this gene were studied regarding their association with CV disease in RA. With respect to the variant located in the 5′ flanking region at position −174 (G > C; rs1800795), previously associated with higher transcriptional activity and increased serum levels traditional CV risk factors. When the influence of this polymorphism in subclinical CV disease was analyzed, although the homozygote for the minor allele showed higher and lower mean values of two surrogate markers of subclinical atherosclerosis, cIMT and FMD, respectively, no statistical significant differences were observed.

The variant located at the −1031 position (T > C, rs1799964) has not shown influence in the transcription activity of the gene [56], neither has been associated to a higher risk of CV disease. However, this polymorphism has been associated with a more proatherogenic lipid profile [57].

Polymorphisms located in the LTA gene (that codes for the TNF-β or lymphotoxin α) have also been studied. This cytokine has been implicated in the early stages of the vascular inflammatory process [58], inducing expression of leukocyte adhesion molecules (LAMs) in endothelial cells. Also, in mice models, its concentration has been correlated with plaque size [59]. The variant located at position +252 (A > G) of the LTA gene has been associated with a higher risk of IHD in a cohort of UK Caucasian RA patients [26], with independence of traditional CV risk factors, RA characteristics, and medication.

Galectin-2 is a soluble beta-galactoside binding lectin, that interacts with TNF-β and it is required for a correct secretion of the latter into the medium [60]. The polymorphism analyzed regarding its association with CV disease is located in intron 1, at position +3279 (C > T) and has been associated to a decreased transcriptional activity of the LGALS2 gene. Although this variant showed association to IHD in general population [60], no association was observed in a cohort of UK Caucasian RA patients [26]. However, the minor allele T showed a significant association, even after being adjusted by confounders, with a lower value of diastolic blood pressure [61].

A polymorphism located in the TNF-α receptor II (TNFRSF1B) was also studied, located at position +676 (T > G; substitution of methionine for arginine at codon position 196). No association neither with IHD nor with stroke in a cohort of Sweden Caucasian RA patients was observed. However, this variant showed a significant association with a higher risk of hypertension in the same study [27].

4. Cytokine and Chemokine Genes

IL-6 is a cytokine with pleiotropic and redundant actions. IL-6 is also a major regulator of the synthesis of acute-phase reactants by the liver [62]. This cytokine is produced by a wide variety of cells, and it is involved in both RA and atherosclerosis pathogenesis [63, 64]: circulating IL-6 concentration has been associated with endothelial activation and treatment with traditional disease modifying antirheumatic drugs, resulting in a suppression of IL-6, has been associated to a reduced endothelial activation in patients with RA [65, 66]. Three polymorphisms of this gene were studied regarding their association with CV disease in RA. With respect to the variant located in the 5′ flanking region at position −174 (G > C; rs1800795), previously associated with higher transcriptional activity and increased serum levels...
| Study                          | Population                  | Gene/polymorphism | Controls/cases | Case definition | Results                                                                                                                                 |
|-------------------------------|-----------------------------|-------------------|----------------|----------------|-----------------------------------------------------------------------------------------------------------------------------------------|
| Gonzalez-Gay et al. [19]       | Caucasians from Spain       | HLA DRB1          | 143/39         | CV mortality, CV disease | HLA DRB1 *0404 allele is associated to an increased risk of CV event and CV mortality. HLA DRB1 *01 and 04 are associated to higher CV mortality risk. 2 copies of the SE are associated to a higher CV mortality in RF+ or anti-CCP+ patients. In the latter group, the risk is higher in smokers. HLA DRB1 SE genotypes are associated to higher IHD mortality risk, especially *0101/*0401 and *0404/*0404. HLA DRB1 *04 alleles, especially the *0404/*0404 genotype, are associated to lower FMD. Minor allele is associated to higher rate CV events, especially in subjects carrying at least a copy of the SE. |
| Farragher et al. [20]          | Caucasians from the UK      | HLA DRB1          | †              | CV mortality    | FMD                                                                                                                                 |
| Mattey et al. [21]             | Caucasians from the UK      | HLA DRB1          | 767/53 CV deaths | IHD mortality   | FMD                                                                                                                                 |
| Gonzalez-Juanatey et al. [22]  | Caucasians from Spain       | HLA DRB1          | 55 cases       | FMD            | FMD                                                                                                                                 |
| Rojas-Villarraga et al. [23]   | Colombian, ethnicity not clarified in the paper | HLA DRB1          | 140 cases      | FMD, cIMT       | FMD                                                                                                                                 |
| Garcia-Bermudez et al. [24]    | Caucasians from Spain       | MHC2TA rs3087456, rs4774 | 1069/233       | CV disease      | HLA DRB1 SE genotypes are associated to the presence of AP. \n| Rodríguez-Rodríguez et al. [25] | Caucasians from Spain      | TNFA rs1800629    | 494/93          | CV disease      | MINOR allele is associated to higher rate CV events, especially in subjects carrying at least a copy of the SE. |
| Panoulas et al. [26]           | Caucasians from the UK (95.9%) | LTA + 252 (A > G) | 301/87         | CV disease      | LTA minor allele is associated to higher risk of MI and HF. \n| Årlestig et al. [27]           | Caucasians from Sweden      | TNFRSF1B + 676 (T > G) | 354/113         | IHD, stroke     | No association. Carriers of the minor allele are associated to a higher risk of CV disease. |
| Panoulas et al. [28]           | Caucasians from the UK      | IL6 rs1800795     | 295/88          | CV disease      | No association. |
| López-Mejías et al. [29]       | Caucasians from Spain       | IL6 rs1800795, 2069827, rs2069840 | 1030/220        | CV disease      | No association. |
| Study                          | Population             | Gene/polymorphism       | Controls/cases | Case definition          | Results                                                                 |
|-------------------------------|------------------------|-------------------------|----------------|--------------------------|--------------------------------------------------------------------------|
| Palomino-Morales et al. [30]  | Caucasians from Spain  | IL6 rs1800795           | 311 cases      | FMD                      | Carriers of the minor allele are associated to lower FMD values.          |
| López-Mejías et al. [31]      | Caucasians from Spain  | IL6R rs2228145, rs2228044 | 1030/220       | CV disease               | No association.                                                          |
| Radstake et al. [32]          | Caucasians from The Netherlands | MIF − 794 (CATT5–8), −173 (G > C) | 241/14 | CV disease               | No association.                                                          |
| Palomino-Morales et al. [33]  | Caucasians from Spain  | MIF − 173 (G > C)       | 249/44         | CV disease, FMD, NTG, and cIMT | No association.                                                          |
| Rodríguez-Rodríguez et al. [34] | Caucasians from Spain  | CCR5 rs333              | 558/87         | CV disease, FMD, NTG, and cIMT | Minor allele is associated to lower risk of CV disease and a normal FMD value. |
| Farragher et al. [35]         | Caucasians from the UK | CCL21 rs2812378         | 4              | CV mortality              | Minor allele is associated to a higher CV mortality risk.               |
| López-Mejías et al. [36]      | Caucasians from Spain  | CXCL12 rs501120         | 1083/238       | CV disease, FMD, NTG, and cIMT | No association.                                                          |
| Rodríguez-Rodríguez et al. [37] | Caucasians from Spain  | RETN rs1862513          | 553/115        | CV disease, FMD, NTG, and cIMT | No association.                                                          |
| Rodríguez-Rodríguez et al. [38] | Caucasians from Spain  | ADIPQ rs266729, rs1501299 | 555/119        | CV disease, FMD, NTG, and cIMT | No association.                                                          |
| García-Bermúdez et al. [39]   | Caucasians from Spain  | LEP rs2167270           | 655/118        | CV disease, FMD, NTG, and cIMT | No association.                                                          |
| García-Bermúdez et al. [40]   | Caucasians from Spain  | NAMPT rs9770242, rs59744560 | 1035/161       | CV disease, FMD, NTG, and cIMT | No association.                                                          |
| Gonzalez-Gay et al. [41]      | Caucasians from Spain  | NOS3 + 5557; G > T NOS2A microsatellite CCTT, −786 (C > T) | 143/39         | CV disease               | No association. Association of minor allele with higher risk of CV disease in carriers of the HLA-DRB1 * 0404 allele. |
| Study                        | Population          | Gene/polymorphism                      | Controls/cases | Case definition          | Results                                                  |
|-----------------------------|---------------------|----------------------------------------|----------------|--------------------------|----------------------------------------------------------|
| Årlestig et al. [27]         | Caucasians from Sweden | SERPINE1 −675, (4G/5G)                 | 354/113        | IHD, stroke              | 4G allele was associated to a higher risk of IHD.         |
|                             |                     | FGB −455 (G > A)                      |                |                          |                                                          |
|                             |                     | F13A1 34 Val/Leu                       |                |                          |                                                          |
|                             |                     | PTPN22 rs2476601                      |                |                          |                                                          |
|                             |                     | STAT4 rs7574865                       | 532/80         | CV disease               | No association.                                          |
|                             |                     | TRAF1/C5 rs10818488                   |                | FMD, NTG, and cIMT       |                                                          |
| Palomino-Morales et al. [42] | Caucasians from Spain | MTHFR rs1801133, rs1801131              | 532/80         | CV disease               | Minor allele of the rs1801131 variant is associated to higher risk CV disease and lower FMD values. |
|                             |                     |                                      |                | FMD, NTG, and cIMT       |                                                          |
|                             |                     |                                        |                |                          |                                                          |
| Palomino-Morales et al. [43] | Caucasians from Spain | VEGFA rs1570360, rs2010963             | 548/113        | CV disease               | No association.                                          |
|                             |                     |                                        |                | FMD, NTG, and cIMT       |                                                          |
|                             |                     |                                        |                |                          |                                                          |
| Rodríguez-Rodríguez et al. [44] | Caucasians from Spain | GHSR rs512692, rs509035, rs2922126     | 543/116        | CV disease               | No association.                                          |
|                             |                     |                                        |                | FMD, NTG, and cIMT       |                                                          |
|                             |                     |                                        |                |                          |                                                          |
| García-Bermúdez et al. [46]  | Caucasians from Spain | TLR4 rs4986790                        | 1220/261       | CV disease               | No association.                                          |
|                             |                     |                                        |                | FMD, NTG, and cIMT       |                                                          |
|                             |                     |                                        |                |                          |                                                          |
| Terruel et al. [47]         | Caucasians from Spain | ACP1 rs7576247, rs11553742, rs10167992, rs3828329 | 1374/229       | CV disease               | Minor allele of the rs1153742 polymorphism and classic ACP1 C allele are associated to a higher risk CV disease. |
|                             |                     |                                        |                | FMD, NTG, and cIMT       |                                                          |
|                             |                     |                                        |                |                          |                                                          |
| López-Mejías et al. [48]     | Caucasians from Spain | PSRC1 rs599839                        | 128 cases      | FMD, NTG                 | Minor allele is associated to lower FMD.                 |

Anti-CCP: presence of anticyclic citrullinated peptides antibodies, AP: atherosclerotic plaque, cIMT: carotid intima-media thickness, CV: cardiovascular, FMD: endothelial-dependent vasodilation, HF: heart failure, IHD: ischemic heart disease, MI: myocardial infarction, NTG: endothelial-independent vasodilation, RF: rheumatoid factor, and SE: shared epitope.

†: the cohort consisted in 1022 subjects with inflammatory arthritis, of whom 751 were diagnosed of rheumatoid arthritis (RA). A total of 76 subjects died of CV causes among the whole cohort. The number of death among the RA patients was not clarified in the article.

‡: the cohort consisted in 2324 subjects with inflammatory arthritis, of whom 1027 were diagnosed of RA. A total of 216 subjects died of CV causes among the whole cohort. The number of death among the RA patients was not clarified in the article.
of IL-6 [67] in general population, the results have been controversial. A study found a significant association with CV disease [28], adjusting for traditional CV risk factors, but not with a higher risk of hypertension [68], in a relatively small (n = 383) cohort of UK Caucasian RA patients [28]. However, in assessing a larger cohort of patients (n = 1250), our group did not observe any significant association with clinical CV disease in Spanish patients [29], although the minor allele was associated with impairment of FMD in a subgroup of RA patients without clinically evident CV disease [30].

The other two polymorphisms studied (rs2069827 and rs2069840) showed no significant association in the same Spanish Caucasian cohort [29].

Variants located in the two subunits forming the IL-6 receptor were also studied. rs2228145 is located at position +1510 of the IL6R gene (A > C; substitution of aspartame for alanine at codon position 358), and its minor allele is associated to higher plasma levels of the soluble form of the receptor [69, 70] and a protective effect regarding CV disease in the general population [71]. However, our group did not observe any statistical association with clinical or subclinical CV disease [31].

In keeping with the above, the polymorphism rs2228044 located at position +755 of the IL6ST or GP130 gene (C > G; substitution of glycine for arginine at codon position 148) was also analyzed in our RA cohort. However, no significant association with clinical or subclinical CV disease was found [31].

The macrophage migration inhibitory factor (MIF) is a cytokine involved in the pathogenesis of RA and atherosclerosis [72]. Two variants of MIF were studied regarding their potential association with CV disease: a tetranucleotide repeat element starting at position −794 (CATT5−8) and a single-nucleotide polymorphism at position −173 (G > C), both of them were previously associated with higher plasma MIF levels [73]. However, neither of them showed a significant association to CV disease, in two Caucasian RA cohorts from The Netherlands and Spain. The MIF −173 variant was not associated to surrogate markers of subclinical CV disease (endothelial dysfunction or abnormally increased cIMT) either [33].

CCR5 is a chemokine receptor that could be potentially involved in the pathogenesis of both RA and atherosclerosis [74], with a proinflammatory effect. The polymorphism analyzed regarding its association with CV disease was a deletion of 32 base pairs (rs333; with starting position at +676) that leads to a truncated nonfunctional receptor [75]. Consequently, in individuals homozygous for the deletion, CCR5 is removed from the cell surface [76], while heterozygous expresses 20% to 30% of the wild-type normal levels [77]. The protective effect of this deletion regarding CV disease in the general population has not always been confirmed [78, 79]. However, in RA population, our group observed a protective effect of the minor allele [34]. Regarding subclinical atherosclerosis, this variant was associated to a higher (normal) value of FMD but no association with cIMT.

The chemokine CCL21 has also been implicated in the pathogenesis of both RA and atherosclerosis [80, 81]. A polymorphism from this gene (rs2812378) was associated to a higher CV and all-causes mortality risk, in a UK chronic arthritis, including RA, cohort [35].

CXCL12, also known as stromal cell-derived factor-1, highly expressed in the atherosclerotic plaque [82], has been also studied by our group, owed to the recently association of the rs501120 (T > C) polymorphism with CV disease in Caucasians in a recent genome-wide association study (GWAS) [83]. However, we did not observe any significant association with clinical or subclinical CV disease [36].

5. Adipocytokines

Adipose tissue secretes a variety of proteins known as “adipokines” or “adipocytokines” that influence a variety of processes, including metabolism, immunity, and inflammation [84]. Besides, clinical obesity measures, such as body mass index and waist-to-hip ratio, have been recently shown to predict the presence of atherosclerosis in patients with RA from a developed population [85].

At present, the most extensively studied adipocytokines are resistin, adiponectin, leptin, and visfatin.

Resistin plays a proinflammatory role [86]. In RA, a strong correlation between resistin serum levels and markers of inflammation, such as C-reactive protein or erythrocyte sedimentation rate, has been observed [87]. The polymorphism rs1862513, located in the promoter region (C > G; position −420), has previously been associated to a higher risk of cerebrovascular disease in type 2 diabetes mellitus patients, both in Asian [88] and Caucasian [89] populations. No association with coronary arterial disease [90], nor with subclinical atherosclerosis was observed [91]. Regarding RA, our group did not observe a significant association with a higher risk of CV disease [37]. Although not included in the published paper, this polymorphism showed no association with the risk of cerebrovascular ischemic events. Regarding subclinical CV disease, the carriers of the minor allele showed a nonsignificant lower FMD and higher cIMT [37].

Adiponectin exerts at the vascular level an anti-inflammatory and antiatherogenic role [92], with lower serum levels in subjects with CV disease [93]. However, at the joint level, it exerts proinflammatory effects [94], with a correlation between radiologic joint damage and adiponectin serum levels [95]. We have previously reported that in patients with severe RA undergoing anti-TNF-alpha therapy high-grade inflammation was independently and negatively correlated with circulating adiponectin concentrations whereas low adiponectin levels clustered with metabolic syndrome features that reportedly contribute to atherogenesis in RA [96]. Taking these data into account, two variants of the ADIPOQ gene were analyzed by our group regarding their potential association with CV disease. However, none of them was found to be associated with adiponectin plasma levels [97], despite the major genetic regulation in adiponectin synthesis. rs266729, located in 5′UTR (C > G; position −11377), had been associated with a higher risk of type 2 diabetes mellitus in Caucasians [98], and to a higher risk of CV disease, both clinical (in Chinese [99] and in nondiabetic Caucasian subjects [100, 101]) and subclinical (in Caucasian
6. Nitric Oxide Synthase Genes

One of the primary causes of initiation of atherosclerosis is endothelial dysfunction, which leads to altered nitric oxide synthesis (NOS) function and NO synthesis [116]. Both the endothelial NOS (eNOS, NOS3) and the inducible isoform of NOS (iNOS, NOS2) have been studied in connection to CV disease. The variant located at exon 7 of the NOS gene (position +5557; G > T), leading to a glutamate to aspartate substitution at codon position 298, was not associated to a higher risk of CV events [41]. The functional effects of this variant in the enzymatic activity are uncertain [117]. On the other hand, two variants of the NOS2A gene located in the promoter region were analyzed: the microsatellite CCTTT (with a influence in the gene transcriptional activity [118]) and the single nucleotide polymorphism at position −786 (C > T). Neither variants shows a significant association with the risk of CV disease [41]. However, in carriers of the HLADRB1 *0404 allele, these three variants showed association with CV disease [41], suggesting an interaction among different genes.

7. Genes Involved in the Haemostatic Process

The plasminogen activator inhibitor type 1 (PAI-1) is the primary physiologic inhibitor of plasminogen activation in blood [119]. PAI-1 overexpression may compromise normal fibrin clearance mechanisms and promote pathological fibrin deposition and thrombotic events. A polymorphism of this gene, located in the promoter region (at starting position −675, 4G/5G), has previously been associated to CV disease and venous thrombotic episodes [120] in the general population. In RA patients, this variant has also been associated with IHD in a cohort of Swedish patients [27].

The fibrin stabilizing factor, or Factor XIII, has a crucial role in blood coagulation and fibrinolysis, stabilizing the fibrin clot and making the clot more lysis resistant [121]. A variant located at exon 2 (amino acid change from a valine to leucine at codon position 34), previously associated to a decreased clot formation and lower risk of IHD [122], was analyzed regarding its influence in the risk of CV disease in a cohort of Swedish RA patients. However, no differences were observed [27].

Fibrinogen plays a major role in arteriosclerosis and thrombosis [123]: increased plasma levels are an independent risk factor for CV diseases [124]. The polymorphism located at position −455 (G > A) showed no association with a higher risk of CV disease in RA patients [27], despite its association with higher plasma levels [123].

8. Other Genes

Regarding other variants strongly associated to RA different from those located in the HLA region, such as PTPN22, STAT4 and TRAF1/C5, none of them showed a significant association with clinical or subclinical CV disease in a cohort of RA Spanish patients of Caucasian ancestry [42]. In keeping with that, TRAF1/C5 polymorphism was not associated with a higher incidence of mortality due to CV disease in another two Caucasian cohorts [125].

The 5,10-methylene tetrahydrofolate reductase (MTHFR) is an enzyme that catalyzes the transformation of methionine to cysteine. The lack of this enzyme leads to the accumulation of homocysteine, an independent nontraditional risk factor for CV disease [126]. Two variants associated to a lower enzyme activity and higher homocysteine plasma levels [127, 128] were analyzed by our group. The polymorphism rs1801133 (C > T; position +677; amino acid substitution alanine to valine at codon position 222; exon 4) showed no significant association. Nevertheless, the variant rs1801131 (A > G; position +1298; amino acid change from glutamine to alanine at codon position 429; exon 7) was associated with a higher risk of CV disease and endothelial dysfunction manifested by lower values of FMD [43].

Neovascularization is an important process in the development and stabilization of atherosclerotic plaques [129]. One of the most important pro-angiogenic factors is VEGF. Its expression can be stimulated through both hypoxia [130] and proinflammatory cytokines [131]. Several polymorphisms have been described within the VEGFA promoter and
5'UTR regions, which regulate its expression at the post-transcriptional level [132]. We selected two variants with functional relevance: rs1570360 located within the VEGFA promoter (G > A; position –1154) and rs2010963 located within 5'UTR (G > C; position –634), both associated to lower VEGFA transcription [132]. Also, the latter has been associated to higher serum VEGF levels [135]. The major allele C of the –634 variant has been associated to Bechet disease [134], giant cell arteritis [135] and the presence of severe ischemic complications in the latter [136], and clinical CV disease but only in type 2 diabetes mellitus subjects [133]. However, the –1154 polymorphism has not shown association with CV disease [137]. In our study, we did not observe significant association between any of these two VEGFA polymorphisms and clinical or subclinical CV disease in RA patients [44].

GHSR codes for the receptor of the growth hormone secretagogue, ghrelin. Besides its metabolic and endocrine effects [138], this receptor also mediates anti-inflammatory [139] and antiatherogenic [140] effects through its expression in immune and vascular cells.

In RA patients with severe disease undergoing anti-TNF-alpha therapy, we found an increase in ghrelin concentrations upon TNF-α blockade that was associated with reductions in P-selectin, a biomarker of endothelial activation that predicts CV event rates [141]. Three polymorphisms were analyzed by our group rs512692, located in the 5'UTR region, rs509035, located in the intron, and rs2922126, located in the promoter region. Previously, these 3 variants had showed no association with RA [142]. Regarding CV disease, both rs509035 and rs512692 were associated to IHD in the Caucasian general population [143], while rs512692 was not. In our study, we found no association with clinical or subclinical CV disease for any of the variants [45].

Toll-like receptor 4 (TLR4) plays a key role in the activation of innate immune responses and has been implicated in the initiation, progression, and plaque destabilization stages of atherosclerosis [144]. Our group studied the role of the TLR4 gene polymorphism rs4986790 (position +896; A > G; amino acid substitution from aspartame to glycine at codon position 299), previously associated with an attenuated signaling leading to a dampened response to LPS [145] and with a lower risk of proatherogenic metabolic traits [146]. However, in a German cohort of Caucasian ancestry, this variant did not show association with a lower risk of IHD. In keeping with that, in our population, we did not observe any significant association with a lower risk of clinical nor subclinical CV disease [46].

Low-molecular-weight phosphotyrosine phosphatase (encoded by ACP1) plays a key role as regulator of signalling pathways in receptor-stimulated immune cells, in growth factor regulation, in cellular adhesion, and in T-cell development and lymphocyte activation [147]. Three common alleles have been described in Caucasian populations (ACP1*A, ACP1*B, ACP1*C), tagged by two SNPs: rs7576247 (A > G; amino acid substitution from arginine to glutamine at codon position 105; exon 6) and s11553742 (C > T; synonymous polymorphism at codon position 44; exon 3). Another two variants, previously associated to quantitative traits related to type 2 diabetes mellitus [148], were also studied by our group: rs10167992 and rs3828329. We observed that the minor allele of the rs11553742 variant was associated to a significant higher risk of CV disease. Likewise, the classic allele ACPI*4 (defined by the presence of the minor allele of the rs11553742 polymorphism and the major allele of the variant rs7576247) also showed a significant association with a higher risk. Both associations remained after adjustment by sociodemography and tradition CV risk factors [47].

Based on the results of previous GWAS [149], a polymorphism located in the region 1p13.3, near the gene PSRC1 (proline-serine-rich coiled coil protein 1), was analyzed in our group regarding its role in subclinical CV disease. In accordance with those data, we observed a significant association between the minor allele and lower values of FMD [48].

9. Conclusions

In the last years, an important advance in the knowledge of the genetic basis of CV disease has taken place, both in general population and in RA patients. However, in aggregate, the discovered variants explain only a small fraction of the heritability of CV disease (estimated to be up to 30–60% in the general population [13]), probably in part due to the limited power of previous studies to discover effects of modest size. Until now, research performed in RA patients was based on hypothesis-driven candidate gene association studies, such as the ones performed in this work. This approach provides a focused view of genomic regions of interest, allowing targeting putative functional variant. Also, this design is especially useful when allele frequencies are low, effect sizes are small, or the study population is limited [150]. However, this kind of approach has its own pitfalls, such as the lack of replication of results, presence of false positive results, and little account for genetic heterogeneity. To overcome these limitations, among other things, it would be necessary to increase the number of individuals, in both cases and controls. To that end, it would be necessary the joint collaboration of different groups to replicate the results in different populations. Also, pooling various cohorts would allow improving the detection of modest genetic effects.

Taking into account the influence of different genetic markers in the risk of CV disease and CV mortality, we consider that it is maybe the time to start routinely assessing some of these markers in order to identify those RA subjects at very high risk of developing CV disease. For example, we propose to assess the HLA-DRB1 genotype at the moment of RA diagnosis, due to its repeated association with higher risk of CV mortality, especially in those patients who are anti-CCP-positive and/or current smokers. Besides, these patients at higher risk would probably benefit from a thorough and more intense management of their classic CV risk factors, as, in example, those subjects with a previous CV event.

A better understanding of the genetic basis of CV disease in RA will grant a better comprehension of the signaling pathways and the knowledge of different molecules implicated in the pathogenesis of this condition. The results
derived from these studies will be useful in the discovery of new therapeutic targets and in the development of new drugs that aim to decrease the CV mortality observed in patients with RA.

Conflict of Interests

The authors declare that they have no conflict of interests.

Authors’ Contribution

Drs González-Gay and Martin shared senior authorship.

Acknowledgments

This study was supported by 2 Grants from the Fondo de Investigaciones Sanitarias, PI06-0024 and PI09/007/48 (Spain). This work was partially supported by the RETICS Program, RD08/0075 (RIER), from Instituto de Salud Carlos III. M. García-Bermúdez is the beneficiary of a grant from the Fundación Española de Reumatología (FER).

References

[1] C. Gonzalez-Juaneatey, J. Llorca, A. Testa, J. Revuelta, C. Garcia-Porrua, and M. A. Gonzalez-Gay, “Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease,” Medicine, vol. 82, no. 6, pp. 407–413, 2003.

[2] M. T. Nurmohamed, “Cardiovascular risk in rheumatoid arthritis,” Autoimmunity Reviews, vol. 8, no. 8, pp. 663–667, 2009.

[3] I. D. del Rincón, K. Williams, M. P. Stern, G. L. Freeman, and A. Escalante, “High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors,” Arthritis and Rheumatism, vol. 44, no. 12, pp. 2737–2745, 2001.

[4] J. F. Boyer, P. A. Gourraud, A. Cantagrel, J. L. Davignon, and A. Constantin, “Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis,” Joint Bone Spine, vol. 78, no. 2, pp. 179–183, 2011.

[5] N. Sattar, D. W. McCarey, H. Capell, and I. B. McInnes, “Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis,” Circulation, vol. 108, no. 24, pp. 2957–2963, 2003.

[6] D. L. Scott, F. Wolfe, and T. W. J. Huizinga, “Rheumatoid arthritis,” The Lancet, vol. 376, no. 9746, pp. 1094–1108, 2010.

[7] G. K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1685–1695, 2005.

[8] V. Pasci and E. T. H. Yeh, “A tale of two diseases: atherosclerosis and rheumatoid arthritis,” Circulation, vol. 100, no. 21, pp. 2124–2126, 1999.

[9] L. Kláreskog, A. I. Catrina, and S. Paget, “Rheumatoid arthritis,” The Lancet, vol. 373, no. 9664, pp. 659–672, 2009.

[10] J. F. Peden and M. Farrall, “Thirty-five common variants for coronary artery disease: the fruits of much collaborative labour,” Human Molecular Genetics, vol. 20, no. R2, pp. R198–R205, 2011.

[11] M. A. Gonzalez-Gay, C. Gonzalez-Juaneatey, and J. Martin, “Rheumatoid arthritis: a disease associated with accelerated atherogenesis,” Seminars in Arthritis and Rheumatism, vol. 35, no. 1, pp. 8–17, 2005.

[12] A. J. MacGregor, H. Sniider, A. S. Rigby et al., “Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins,” Arthritis and Rheumatism, vol. 43, no. 1, pp. 30–37, 2000.

[13] M. E. Marenberg, N. Risch, L. F. Berkman, B. Floderus, and U. de Faire, “Genetic susceptibility to death from coronary heart disease in a study of twins,” The New England Journal of Medicine, vol. 330, no. 15, pp. 1041–1046, 1994.

[14] E. Bartoloni, A. Alunno, O. Bistoni, and R. Gerli, “How early is the atherosclerotic risk in rheumatoid arthritis?” Autoimmunity Reviews, vol. 9, no. 10, pp. 701–707, 2010.

[15] M. A. Gonzalez-Gay, C. Gonzalez-Juaneatey, T. R. Vazquez-Rodriguez, J. Martin, and J. Llorca, “Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 38, no. 2, pp. 67–70, 2008.

[16] G. Kerkes, P. Soltesz, M. T. Nurmohamed et al., “Validated methods for assessment of subclinical atherosclerosis in rheumatology,” Nature Reviews Rheumatology, vol. 8, no. 4, pp. 224–234, 2012.

[17] C. Gonzalez-Juaneatey, J. Llorca, J. Martin, and M. A. Gonzalez-Gay, “Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 38, no. 5, pp. 366–371, 2009.

[18] M. R. Evans, A. Escalante, D. E. Battafarano, G. L. Freeman, D. H. O’Leary, and I. del Rincón, “Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis,” Arthritis and Rheumatism, vol. 63, no. 5, pp. 1211–1220, 2011.

[19] M. A. Gonzalez-Gay, C. Gonzalez-Juaneatey, M. J. Lopez-Diaz et al., “HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis,” Arthritis and Rheumatism, vol. 57, no. 1, pp. 125–132, 2007.

[20] T. M. Farragher, N. J. Goodson, H. Naseem et al., “Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis,” Arthritis and Rheumatism, vol. 58, no. 2, pp. 359–369, 2008.

[21] D. L. Mattye, W. Thomson, W. E. R. Ollier et al., “Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study,” Arthritis and Rheumatism, vol. 56, no. 5, pp. 1408–1416, 2007.

[22] C. Gonzalez-Juaneatey, A. Testa, A. Garcia-Castelo et al., “HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis,” The American Journal of Medicine, vol. 114, no. 8, pp. 647–652, 2003.

[23] A. Rojas-Villarraga, O. D. Ortega-Hernandez, L. F. Gomez et al., “Risk factors associated with different stages of atherosclerosis in Colombian patients with rheumatoid arthritis,” Seminars in Arthritis and Rheumatism, vol. 38, no. 2, pp. 71–82, 2008.

[24] M. Garcia-Bermudez, C. Gonzalez-Juaneatey, R. Lopez-Mejias et al., “Influence of MHCIIITA rs3087456 and rs4774 polymorphisms in the susceptibility to cardiovascular disease of patients with rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 30, pp. 51–57, 2012.
[25] L. Rodríguez-Rodríguez, C. González-Juanatey, R. Palomino-Morales et al., "TNFA-308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis," *Atherosclerosis*, vol. 216, no. 1, pp. 125–130, 2011.

[26] V. F. Panoulas, S. N. Nikas, J. P. Smith et al., “Lymphotoxin 252A > G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 67, no. 11, pp. 1550–1556, 2008.

[27] L. Árlestig, S. W. Jonsson, B. Stegmayr, and S. Rantapää-Dahlqvist, "Polymorphism of genes related to cardiovascular disease in patients with rheumatoid arthritis," *Clinical and Experimental Rheumatology*, vol. 25, no. 6, pp. 866–871, 2007.

[28] V. F. Panoulas, A. Stavropoulos-Kalinoglou, G. S. Metsios et al., “Association of interleukin-6 (IL-6)-174G/C gene polymorphism with cardiovascular disease in patients with rheumatoid arthritis: the role of obesity and smoking,” *Atherosclerosis*, vol. 204, no. 1, pp. 178–183, 2009.

[29] R. López-Mejías, M. García-Bermúdez, C. González-Juanatey et al., “Lack of association between IL6 single nucleotide polymorphisms and cardiovascular disease in Spanish patients with rheumatoid arthritis,” *Atherosclerosis*, vol. 219, no. 2, pp. 655–658, 2011.

[30] R. Palomino-Morales, C. Gonzalez-Juanatey, T. R. Vazquez-Rodriguez et al., "Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 27, no. 6, pp. 964–970, 2009.

[31] R. López-Mejías, M. García-Bermúdez, C. González-Juanatey et al., "Lack of association of IL6R rs2228145 and IL6ST/gp130 rs2228044 gene polymorphisms with cardiovascular disease in patients with rheumatoid arthritis," *Tissue Antigens*, vol. 78, no. 6, pp. 438–441, 2011.

[32] T. R. D. J. Radstake, J. Fransen, P. L. C. M. van Riel, E. Toonen, M. Coenen, and R. Donn, “Functional variants of the macrophage migration inhibitory factor do not infer risk of cardiovascular disease in rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 67, no. 1, pp. 134–135, 2008.

[33] R. Palomino-Morales, C. González-Juanatey, T. R. Vazquez-Rodriguez et al., "Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from northwestern Spain," *Clinical and Experimental Rheumatology*, vol. 28, no. 1, pp. 68–72, 2010.

[34] L. Rodríguez-Rodríguez, C. González-Juanatey, M. García-Bermúdez et al., "CCR5Δ32 variant and cardiovascular disease in patients with rheumatoid arthritis: a cohort study," *Arthritis Research and Therapy*, vol. 13, no. 4, article R133, 2011.

[35] T. M. Farragher, D. Plant, E. Flynn et al., “Association of a rheumatoid arthritis susceptibility variant at the CCL21 locus with premature mortality in inflammatory polyarthriti patients,” *Arthritis Care and Research*, vol. 62, no. 5, pp. 676–682, 2010.

[36] R. López-Mejías, M. García-Bermúdez, C. González-Juanatey et al., "Lack of association between the CXCL12 rs501120 polymorphism and cardiovascular disease in Spanish patients with rheumatoid arthritis,” *Human Immunology*, vol. 73, no. 5, pp. 543–546, 2012.

[37] L. Rodríguez-Rodríguez, M. García-Bermúdez, C. González-Juanatey et al., “Lack of association between RETN rs1862513 polymorphism and cardiovascular disease in rheumatoid arthritis patients,” *Clinical and Experimental Rheumatology*, vol. 29, no. 1, pp. 19–25, 2011.

[38] L. Rodríguez-Rodríguez, M. García-Bermúdez, C. González-Juanatey et al., "Lack of association between ADIPOQ rs266729 and ADIPOQ rs1501299 polymorphisms and cardiovascular disease in rheumatoid arthritis patients," *Tissue Antigens*, vol. 77, no. 1, pp. 74–78, 2011.

[39] M. García-Bermúdez, C. González-Juanatey, L. Rodríguez-Rodríguez et al., "Lack of association between A1298C polymorphism in the MTHFR DNA and Cell Biology, vol. 31, no. 4, article R42, 2012.

[40] M. A. Gonzalez-Gay, C. Gonzalez-Juanatey, and W. E. Ollier, "Endothelial dysfunction in rheumatoid arthritis: influence of HLA-DRB1 alleles,” *Autoimmunity Reviews*, vol. 3, no. 4, pp. 301–304, 2004.

[41] R. Gerli, E. B. Boci, Y. Shiner, G. Vaudel, S. Moscatelli, and Y. Shoenfeld, "Association of anti-cyclic citrullinated peptide...
antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 67, no. 5, pp. 724–725, 2008.

[51] S. LeibundGut-Landmann, J. M. Waldburger, M. Krawczyk et al., “Specificity and expression of CIITA, the master regulator of MHC class II genes,” *European Journal of Immunology*, vol. 34, no. 6, pp. 1513–1525, 2004.

[52] G. Buttice, J. Miller, L. Wang, and B. D. Smith, “Interferon-γ induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells,” *Circulation Research*, vol. 98, no. 4, pp. 472–479, 2006.

[53] M. Swanberg, O. Lidman, L. Padyukov et al., “MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction,” *Nature Genetics*, vol. 37, no. 5, pp. 486–494, 2005.

[54] G. Bouma, J. B. A. Crusius, M. Oudkerk Pool et al., “Secretion of tumour necrosis factor α and lymphotoxin-α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease,” *Scandinavian Journal of Immunology*, vol. 43, no. 4, pp. 456–463, 1996.

[55] M. M. Elahi, K. Asotra, B. M. Matata, and S. S. Mastana, “Tumor necrosis factor α—308 gene locus promoter polymorphism: an analysis of association with health and disease,” *Biochimica et Biophysica Acta*, vol. 1792, no. 3, pp. 163–172, 2009.

[56] E. L. Kaijzel, J. P. Bayley, M. V. van Krugten et al., “Allele-specific quantification of tumour necrosis factor α (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals,” *Genes and Immunity*, vol. 2, no. 3, pp. 135–144, 2001.

[57] J. C. Vallé, S. Paredes, J. Girona et al., “Tumor necrosis factor-α-1031 T/C polymorphism is associated with smaller and more proatherogenic low density lipoprotein particles in patients with rheumatoid arthritis,” *Journal of Rheumatology*, vol. 35, no. 9, pp. 1697–1703, 2008.

[58] T. Tanaka and K. Ozaki, “Inflammation as a risk factor for myocardial infarction,” *Journal of Human Genetics*, vol. 172, 2009.

[59] S. A. Schreyer, C. M. Vick, and R. C. Leboeuf, “Loss of lymphotoxin-α but not tumor necrosis factor-α reduces atherosclerosis in mice,” *The Journal of Biological Chemistry*, vol. 277, no. 14, pp. 12364–12368, 2002.

[60] K. Ozaki, K. Inoue, H. Sato et al., “Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro,” *Nature*, vol. 429, no. 6987, pp. 72–75, 2004.

[61] V. F. Panoulas, K. M. J. Douglas, J. P. Smith et al., “Galectin-2 (LGALS2) 3279C/T polymorphism may be independently associated with diastolic blood pressure in patients with rheumatoid arthritis,” *Clinical and Experimental Hypertension*, vol. 31, no. 2, pp. 93–104, 2009.

[62] D. A. Papanicolaou, R. L. Wilder, S. C. Manolagas, and G. P. Chrousos, “The pathophysiological roles of interleukin-6 in human disease,” *Annals of Internal Medicine*, vol. 128, no. 2, pp. 127–137, 1998.

[63] F. A. Houssiau, J. P. Devogelaer, J. van Damme, C. Nagant de Deuchaisnes, and J. van Snick, “Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis,” *Arthritis and Rheumatism*, vol. 31, no. 6, pp. 784–788, 1988.

[64] J. Danesh, S. Kaptoge, A. G. Mann et al., “Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review,” *PLoS Medicine*, vol. 5, no. 4, article e78, 2008.

[65] P. H. Dessein, B. I. Joffe, and S. Singh, “Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis,” *Arthritis Research & Therapy*, vol. 7, no. 3, pp. R634–R643, 2005.

[66] P. H. Dessein and B. I. Joffe, “Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 24, no. 2, pp. 161–167, 2006.

[67] K. G. Jones, D. J. Brull, L. C. Brown et al., “Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms,” *Circulation*, vol. 103, no. 18, pp. 2260–2265, 2001.

[68] L. A. LeibundGut-Landmann, J. M. Waldburger, M. Krawczyk et al., “Secretion of tumour necrosis factor α and lymphotoxin-α in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease,” *Scandinavian Journal of Immunology*, vol. 43, no. 4, pp. 456–463, 1996.

[69] M. Swanberg, O. Lidman, L. Padyukov et al., “MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction,” *Nature Genetics*, vol. 37, no. 5, pp. 486–494, 2005.

[70] G. Butticé, J. M. Miller, L. Wang, and B. D. Smith, “Interferon-γ induces major histocompatibility class II transactivator (CIITA), which mediates collagen repression and major histocompatibility class II activation by human aortic smooth muscle cells,” *Circulation Research*, vol. 98, no. 4, pp. 472–479, 2006.

[71] N. Sarwar and A. S. Butterworth, “Interleukin-6 receptor associations with the rs8192284 IL6R polymorphism and with disease activity,” *Rheumatology International*, vol. 31, no. 3, pp. 409–413, 2011.

[72] L. l. Santos and E. F. Morand, “Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis,” *Clinical Chimica Acta*, vol. 399, no. 1–2, pp. 1–7, 2009.

[73] T. R. D. J. Radstake, F. C. G. J. Sweep, P. Welsing et al., “Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor,” *Arthritis and Rheumatism*, vol. 52, no. 10, pp. 3020–3029, 2005.

[74] K. L. Jones, J. J. Maguire, and A. P. Davenport, “Chemokine receptor CCR5: from AIDS to atherosclerosis,” *British Journal of Pharmacology*, vol. 162, no. 7, pp. 1453–1469, 2011.

[75] M. Samson, F. Libert, B. J. Doranz et al., “Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR5 chemokine receptor gene,” *Nature*, vol. 382, no. 6593, pp. 722–725, 1996.

[76] M. Benkirane, D. Y. Jin, R. A. Koup, and K. T. Jeang, “Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32,” *The Journal of Biological Chemistry*, vol. 272, no. 49, pp. 30603–30606, 1997.

[77] S. E. Pacheco, R. A. Gibbs, A. Ansari-Lari, and P. Rogers, “Intranasal immunization with HIV reverse transcriptase: effect of dose in the induction of helper T cell type 1 and 2 immunity,” *AIDS Research and Human Retroviruses*, vol. 16, no. 18, pp. 2009–2017, 2000.

[78] C. R. Balisterri, G. Candore, M. Caruso, E. Incalcaterra, C. Franceschi, and C. Caruso, “Role of polymorphisms of CC-chemokine receptor-5 gene in acute myocardial infarction and biological implications for longevity,” *Haematologica*, vol. 93, no. 4, pp. 637–638, 2008.

[79] J. K. Pai, P. Kraf, C. C. Cannuscio et al., “Polymorphisms in the CC-chemokine receptor-2 (CCR2) and -5 (CCR5)
genes and risk of coronary heart disease among US women,” *Atherosclerosis*, vol. 186, no. 1, pp. 132–139, 2006.

[80] A. Manzo, S. Paoletti, M. Carulli et al., “Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis,” *European Journal of Immunology*, vol. 35, no. 5, pp. 1347–1359, 2005.

[81] E. Trogan, J. E. Feig, S. Dogan et al., “Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 103, no. 10, pp. 3781–3786, 2006.

[82] S. Abi-Younes, A. Sauty, F. Mach, G. K. Sukhova, P. Libby, and A. D. Luster, “The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques,” *Circulation Research*, vol. 86, no. 2, pp. 131–138, 2000.

[83] P. R. Burton, D. G. Clayton, L. R. Cardon et al., “Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls,” *Nature*, vol. 447, no. 7145, pp. 661–678, 2007.

[84] P. Traylor and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” *The British Journal of Nutrition*, vol. 92, no. 3, pp. 347–355, 2004.

[85] A. Solomon, G. R. Norton, A. J. Woodiwiss, and P. H. Dessein, “Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study,” *Arthritis Research and Therapy*, vol. 14, no. 2, Article ID R67, 2012.

[86] M. P. Reilly, M. Lehrke, M. L. Wolfe, A. Rohatgi, M. A. Lazar, and D. J. Rader, “Resistant is an inflammatory marker of atherosclerosis in humans,” *Circulation*, vol. 111, no. 7, pp. 932–939, 2005.

[87] M. A. Gonzalez-Gay, M. T. Garcia-Unzueta, C. Gonzalez-Juanatey et al., “Anti-TNF-α therapy modulates resistin in patients with rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 26, no. 2, pp. 311–316, 2008.

[88] T. Tsuchikawa, E. Nakashima, A. Watarai et al., “Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients,” *Diabetes Research and Clinical Practice*, vol. 84, no. 2, pp. 179–186, 2009.

[89] A. Kunnari, O. Ukkola, and Y. A. Kesaniemi, “Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients,” *Diabetic Medicine*, vol. 22, no. 5, pp. 583–589, 2005.

[90] M. M. Hoffmann, S. Pilz, G. Weihrauch et al., “Effect of the resistin -420C > G polymorphism on cardiovascular disease and mortality,” *Clinical Endocrinology*, vol. 69, no. 2, pp. 344–345, 2008.

[91] A. N. Qasim, T. S. Metkus, M. Tadesse et al., “Resistin gene variation is associated with systemic inflammation but not plasma adipokine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians,” *Clinical Endocrinology*, vol. 70, no. 5, pp. 698–705, 2009.

[92] N. Ouchi, S. Kihara, Y. Arita et al., “Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages,” *Circulation*, vol. 103, no. 8, pp. 1057–1063, 2001.

[93] J. Frystyk, C. Berne, L. Berglund, K. Jensevik, A. Flyvbjerg, and B. Zethelius, “Serum adiponectin is a predictor of coronary heart disease: a population-based 10-year follow-up study in elderly men,” *Journal of Clinical Endocrinology and Metabolism*, vol. 92, no. 2, pp. 571–576, 2007.

[94] H. M. Choi, Y. A. Lee, S. H. Lee et al., “Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators,” *Arthritis Research and Therapy*, vol. 11, no. 6, article R161, 2009.

[95] J. T. Giles, D. M. van der Heijde, and J. M. Bathon, “Association of circulating adiponectin levels with progression of radiographic joint destruction in rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 70, no. 9, pp. 1562–1568, 2011.

[96] M. A. Gonzalez-Gay, J. Llorca, M. T. Garcia-Unzueta et al., “High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 26, no. 4, pp. 596–603, 2008.

[97] J. M. Heid, P. Henneman, A. Hicks et al., “Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: results of genome-wide association analyses including 4659 European individuals,” *Atherosclerosis*, vol. 208, no. 2, pp. 412–420, 2010.

[98] L. Y. Han, Q. H. Wu, M. L. Jiao et al., “Associations between single-nucleotide polymorphisms (+45T > G, +276G > G, -11377C > G, -11391G > A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis,” *Diabetologia*, vol. 54, no. 9, pp. 2303–2314, 2011.

[99] F. Liu, Z. He, S. Deng, H. Zhang, N. Li, and J. Xu, “Association of adiponectin gene polymorphisms with the risk of ischemic stroke in a Chinese Han population,” *Molecular Biology Reports*, vol. 38, no. 3, pp. 1983–1988, 2011.

[100] G. Hoefle, A. Muendlein, C. H. Saely et al., “The -11377 C > G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men,” *Thrombosis and Haemostasis*, vol. 97, no. 3, pp. 451–457, 2007.

[101] D. R. Gable, J. Matin, R. Whitall et al., “Common adiponectin gene variants show different effects on risk of cardiovascular disease and type 2 diabetes in European subjects,” *Annals of Human Genetics*, vol. 71, no. 4, pp. 453–466, 2007.

[102] S. Patel, A. Flyvbjerg, M. Kozakova et al., “Variation in the ADIPOQ gene promoter is associated with carotid intima media thickness independent of plasma adiponectin levels in healthy subjects,” *European Heart Journal*, vol. 29, no. 3, pp. 386–393, 2008.

[103] B. D. Chiodini, C. Specchia, F. Gori et al., “Adiponectin gene polymorphisms and their effect on the risk of myocardial infarction and type 2 diabetes: an association study in an Italian population,” *Therapeutic Advances in Cardiovascular Disease*, vol. 4, no. 4, pp. 223–230, 2010.

[104] C. Menzaghi, V. Trischitta, and A. Doria, “Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease,” *Diabetes*, vol. 56, no. 5, pp. 1198–1209, 2007.

[105] K. M. Tong, D. C. Shieh, C. P. Chen et al., “Leptin induces IL-8 expression via leptin receptor, IRS-1, PI3K. Akt cascade and promotion of NF-kB/p300 binding in human synovial fibroblasts,” *Cellular Signalling*, vol. 20, no. 8, pp. 1478–1488, 2008.

[106] F. Galletti, A. Barbato, M. Versiero et al., “Circulating leptin levels predict the development of metabolic syndrome in
middle-aged men: an 8-year follow-up study,” *Journal of Hypertension*, vol. 25, no. 8, pp. 1671–1677, 2007.

[107] M. Otero, R. Lago, R. Gomez et al., “Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 65, no. 9, pp. 1198–1201, 2006.

[108] M. A. Gonzalez-Gay, M. T. Garcia-Unzueta, A. Berja et al., “Anti-TNF-α therapy does not modulate leptin in patients with severe rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 27, no. 2, pp. 222–228, 2009.

[109] J. Hager, K. Clement, S. Francke et al., “A polymorphism in the 5′ untranslated region of the human ob gene is associated with low leptin levels,” *International Journal of Obesity*, vol. 22, no. 3, pp. 200–205, 1998.

[110] W. D. Li, D. R. Reed, J. H. Lee et al., “Sequence variants in WAPL are associated with obesity in women,” *Annals of Human Genetics*, vol. 63, no. 3, pp. 227–234, 1999.

[111] F. Brentano, O. Schorr, C. Ospelt et al., “Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities,” *Arthritis and Rheumatism*, vol. 56, no. 9, pp. 2829–2839, 2007.

[112] T. B. Dahl, A. Yndestad, M. Skjelland et al., “Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization,” *Circulation*, vol. 115, no. 8, pp. 972–980, 2007.

[113] S. D. Bailey, J. C. Loredo-Osti, P. Lepage et al., “Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population,” *Diabetes*, vol. 55, no. 10, pp. 2896–2902, 2006.

[114] L. M. Johansson, L. E. Johansson, and M. Ridderstråle, “The visfatin (PBEF1) G–94T gene polymorphism is associated with increased high-density lipoprotein cholesterol in obese subjects,” *Metabolism*, vol. 57, no. 11, pp. 1558–1562, 2008.

[115] M. A. Gonzalez-Gay, T. R. Vazquez-Rodriguez, M. T. Garcia-Unzueta et al., “Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-α therapy,” *Clinical and Experimental Rheumatology*, vol. 28, no. 1, pp. 56–62, 2010.

[116] A. Chatterjee and J. D. Catravas, “Endothelial nitric oxide (NO) and its pathophysiologic regulation,” *Vascular Pharmacology*, vol. 49, no. 4–6, pp. 134–140, 2008.

[117] J. Paschas, G. L. Cavalleri, L. E. Bautista, L. Smeeth, S. E. Humphries, and A. D. Hingorani, “Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review,” *American Journal of Epidemiology*, vol. 164, no. 10, pp. 921–935, 2006.

[118] Y. Kawaguchi, Y. Kawaguchi, M. Hara et al., “NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity,” *Arthritis Research and Therapy*, vol. 8, no. 4, article R104, 2006.

[119] K. Huber, G. Christ, J. Wojta, and D. Gulba, “Plasminogen activator inhibitor type-1 in cardiovascular disease—status report 2001,” *Thrombosis Research*, vol. 103, supplement 1, pp. S7–S19, 2001.

[120] A. E. Tsantes, G. K. Nikolopoulos, P. G. Bagos, S. Bonovas, P. Kopterides, and G. Vaiopoulos, “The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk,” *Thrombosis Research*, vol. 122, no. 6, pp. 736–742, 2008.
with severe ischemic complications in giant cell arteritis," *Journal of Rheumatology*, vol. 32, no. 9, pp. 1737–1741, 2005.

[137] W. M. Howell, S. Ali, M. J. Rose-Zerilli, and S. Ye, “VEGF polymorphisms and severity of atherosclerosis,” *Journal of Medical Genetics*, vol. 42, no. 6, pp. 485–490, 2005.

[138] R. G. Smith, H. Jiang, and Y. Sun, "Developments in ghrelin biology and potential clinical relevance," *Trends in Endocrinology and Metabolism*, vol. 16, no. 9, pp. 436–442, 2005.

[139] V. D. Dixit, E. M. Schaffer, R. S. Pyle et al., "Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells," *The Journal of Clinical Investigation*, vol. 114, no. 1, pp. 57–66, 2004.

[140] W. G. Li, D. Gavrila, X. Liu et al., "Ghrelin inhibits proinflammatory responses and nuclear factor-κB activation in human endothelial cells," *Circulation*, vol. 109, no. 18, pp. 2221–2226, 2004.

[141] M. A. Gonzalez-Gay, M. T. Garcia-Unzueta, A. Berja et al., "Anti-tumour necrosis factor α therapy modulates ghrelin in patients with severe rheumatoid arthritis," *Annals of the Rheumatic Diseases*, vol. 67, no. 11, pp. 1644–1646, 2008.

[142] G. Robledo, B. Rueda, M. A. Gonzalez-Gay et al., “Association study of ghrelin receptor gene polymorphisms in rheumatoid arthritis,” *Clinical and Experimental Rheumatology*, vol. 28, no. 1, pp. 25–29, 2010.

[143] A. Baessler, M. Fischer, B. Mayer et al., “Epistatic interaction between haplotypes of the ghrelin ligand and receptor genes influence susceptibility to myocardial infarction and coronary artery disease," *Human Molecular Genetics*, vol. 16, no. 8, pp. 887–899, 2007.

[144] K. S. Michelsen, M. H. Wong, P. K. Shah et al., “Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 29, pp. 10679–10684, 2004.

[145] N. C. Arbour, E. Lorenz, B. C. Schutte et al., “TLR4 mutations are associated with endotoxin hyporesponsiveness in humans," *Nature Genetics*, vol. 25, no. 2, pp. 187–191, 2000.

[146] A. P. Steinhardt, F. Aranguren, M. L. Tellechea et al., “A functional nonsynonymous toll-like receptor 4 gene polymorphism is associated with metabolic syndrome, surrogates of insulin resistance, and syndromes of lipid accumulation," *Metabolism*, vol. 59, no. 5, pp. 711–717, 2010.

[147] A. C. S. Souza, S. Azoubel, K. C. S. Queiroz, M. P. Pепelenbosch, and C. V. Ferreira, “From immune response to cancer: a spot on the low molecular weight protein tyrosine phosphatase," *Cellular and Molecular Life Sciences*, vol. 66, no. 7, pp. 1140–1153, 2009.

[148] M. Banci, P. Saccucci, F. D'Annibale et al., "ACP1 genetic polymorphism and coronary artery disease: an association study," *Cardiology*, vol. 113, no. 4, pp. 236–242, 2009.

[149] N. J. Samani, J. Erdmann, A. S. Hall et al., “Genomewide association analysis of coronary artery disease," *The New England Journal of Medicine*, vol. 357, no. 5, pp. 443–453, 2007.

[150] T. J. Jorgensen, I. Ruczinski, B. Kessing, M. W. Smith, Y. Y. Shugart, and A. J. Alberg, “Hypothesis-driven candidate gene association studies: practical design and analytical considerations," *American Journal of Epidemiology*, vol. 170, no. 8, pp. 986–993, 2009.